Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 3/2004

01-05-2004

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

Authors: Stephen Hiscox, Liam Morgan, Denise Barrow, Carol Dutkowski, Alan Wakeling, Robert I. Nicholson

Published in: Clinical & Experimental Metastasis | Issue 3/2004

Login to get access
Metadata
Title
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)
Authors
Stephen Hiscox
Liam Morgan
Denise Barrow
Carol Dutkowski
Alan Wakeling
Robert I. Nicholson
Publication date
01-05-2004
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 3/2004
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/B:CLIN.0000037697.76011.1d

Other articles of this Issue 3/2004

Clinical & Experimental Metastasis 3/2004 Go to the issue

OriginalPaper

Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice

OriginalPaper

Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival

OriginalPaper

Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases

OriginalPaper

ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells

OriginalPaper

A fluorescent orthotopic model of metastatic cervical carcinoma

OriginalPaper

Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits